Efficacy and Safety of Yinlan Yigan Granula in Treating Acute Icteric Viral Hepatitis

YANG Fan,LI Xuewei,LU Junxia,LU Chengzhen,LUO Xinla

2013-01-01

Abstract:Objective To preliminarily evaluate the efficacy and safety of Yinlan Yigan granula in treating acute icteric viral hepatitis with the syndrome of damp- heat in liver and gallbladder and with the syndrome of qi stagnation and blood stasis,thus to supply evidence for phase Ⅲ clinical trial. Methods A multicenter,randomized,double- blind,and positive- medicine paralleled controlled trail was carried out in 120 qualified patients. The treatment group had 60cases,and was administered with Yinlan Yigan granula. The control group also had 60 cases,and was administered with Liganlong granula. The course of treatment lasted 4 weeks. An interview was made on week 1, 2, 3, 4 after medication. The normalization rate of alanine aminotransferase(ALT) and aspartate aminotransferase(AST) was detected,and the changes in total scores of traditional Chinese medical syndromes as well as relevant safety indexes were examined. Results After treatment for 4 weeks,the ALT normalization rate was 81.4 % in the treatment group and was 85.0 % in the control group, and the difference between them was insignificant(P >0.05). The AST normalization rate was 83.1 % in the treatment group and was 88.3 % in the control group,and the difference between them was insignifican(tP>0.05). The differences of the total scores of traditional Chinese medical syndromes were also insignificant between the two groups. The incidence of adverse events was 1.7% in both groups,the difference being not significan(tP>0.05). Conclusion Yinlan Yigan granula is effective and safe in treating acute icteric viral hepatitis through recovering the ALT and AST levels and by relieving the symptoms,and its effect is similar to that of Liganlong granula,indicating that phase Ⅲ clinical trial can be developed.